Drugs / Lentivirus Alpha-gal A transduced stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02800070 | Jul 2016 → Apr 2024 | Fabry disease | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lentivirus Alpha-gal A transduced stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02800070 ↗ |
| Action | Restore | “re-introduction of transduced cells will help increase the levels of alpha-gal A enzyme levels” NCT02800070 ↗ |